Gene · 962
Papers3,378
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,401 to 1,420 of 3,378
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Overexpression of Taspase 1 Predicts Poor Prognosis in Patients with Hepatocellular Carcinoma. | Cancer Manag Res | 2021 | 33758547 | PubTator, text mining | PubMed |
| Mutant ASXL1 induces age-related expansion of phenotypic hematopoietic stem cells through activation of Akt/mTOR pathway. | Nat Commun | 2021 | 33758188 | PubTator, text mining | PubMed |
| Nuclear DEK preserves hematopoietic stem cells potential via NCoR1/HDAC3-Akt1/2-mTOR axis. | J Exp Med | 2021 | 33755722 | PubTator, text mining | PubMed |
| Bioinformatic analyses hinted at augmented T helper 17 cell differentiation and cytokine response as the central mechanism of COVID-19-associated Guillain-Barré syndrome. | Cell Prolif | 2021 | 33751722 | PubTator, text mining | PubMed |
| Therapeutic manipulation of innate lymphoid cells. | JCI Insight | 2021 | 33749662 | PubTator, text mining | PubMed |
| Exploration of a Robust and Prognostic Immune Related Gene Signature for Cervical Squamous Cell Carcinoma. | Front Mol Biosci | 2021 | 33748188 | PubTator, text mining | PubMed |
| Comprehensive Analysis of the Immune and Prognostic Implication of COL6A6 in Lung Adenocarcinoma. | Front Oncol | 2021 | 33747955 | PubTator, text mining | PubMed |
| Analyzing knowledge entities about COVID-19 using entitymetrics. | Scientometrics | 2021 | 33746309 | PubTator, text mining | PubMed |
Standard protocol for the PIGRET assay, a high-throughput reticulocyte Pig-a assay with an immunomagnetic separation, used in the interlaboratory trial organized by the Mammalian Mutagenicity Study Group of the Japanese Environmental Mutagen and Genome Society. | Genes Environ | 2021 | 33743813 | PubTator, text mining | PubMed |
| The Identification and Validation of Two Heterogenous Subtypes and a Risk Signature Based on Ferroptosis in Hepatocellular Carcinoma. | Front Oncol | 2021 | 33738257 | PubTator, text mining | PubMed |
| A profile and review of findings from the Early Markers for Autism study: unique contributions from a population-based case-control study in California. | Mol Autism | 2021 | 33736683 | PubTator, text mining | PubMed |
| Clinical Significance of a Novel Tumor Progression-Associated Immune Signature in Colorectal Adenocarcinoma. | Front Cell Dev Biol | 2021 | 33732694 | PubTator, text mining | PubMed |
| Latent Cytomegalovirus Infection and Previous Capsular Polysaccharide Vaccination Predict Poor Vaccine Responses in Older Adults, Independent of Chronic Kidney Disease. | Clin Infect Dis | 2021 | 33728434 | PubTator, text mining | PubMed |
| Primary thymus tumors: retrospective case analysis at a reference center in Latin America, 2011-2019. | BMC Cancer | 2021 | 33726691 | PubTator, text mining | PubMed |
| GMP-Compliant Universal Antigen Presenting Cells (uAPC) Promote the Metabolic Fitness and Antitumor Activity of Armored Cord Blood CAR-NK Cells. | Front Immunol | 2021 | 33717142 | PubTator, text mining | PubMed |
| Increased Immune-Regulatory Receptor Expression on Effector T Cells as Early Indicators of Relapse Following Autologous Stem Cell Transplantation for Multiple Myeloma. | Front Immunol | 2021 | 33717112 | PubTator, text mining | PubMed |
| Perspectives on Oncolytic Salmonella in Cancer Immunotherapy-A Promising Strategy. | Front Immunol | 2021 | 33717106 | PubTator, text mining | PubMed |
| Minimal role of interleukin 6 and toll-like receptor 2 and 4 in murine models of immune-mediated bone marrow failure. | PLoS One | 2021 | 33711076 | PubTator, text mining | PubMed |
| The immune landscape during the tumorigenesis of cervical cancer. | Cancer Med | 2021 | 33694292 | PubTator, text mining | PubMed |
| Identification of tumor antigens and immune subtypes of cholangiocarcinoma for mRNA vaccine development. | Mol Cancer | 2021 | 33685460 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/962/papers?page=71